GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Price-to-Owner-Earnings

NLS Pharmaceutics (NLS Pharmaceutics) Price-to-Owner-Earnings : (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Price-to-Owner-Earnings?

As of today (2024-06-07), NLS Pharmaceutics's share price is $0.1318. NLS Pharmaceutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NLS Pharmaceutics's Price-to-Owner-Earnings or its related term are showing as below:


NLSP's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-07), NLS Pharmaceutics's share price is $0.1318. NLS Pharmaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.32. Therefore, NLS Pharmaceutics's PE Ratio for today is At Loss.

As of today (2024-06-07), NLS Pharmaceutics's share price is $0.1318. NLS Pharmaceutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.32. Therefore, NLS Pharmaceutics's PE Ratio without NRI for today is At Loss.


NLS Pharmaceutics Price-to-Owner-Earnings Historical Data

The historical data trend for NLS Pharmaceutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Price-to-Owner-Earnings Chart

NLS Pharmaceutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

NLS Pharmaceutics Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NLS Pharmaceutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, NLS Pharmaceutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NLS Pharmaceutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Price-to-Owner-Earnings falls into.



NLS Pharmaceutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NLS Pharmaceutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1318/-0.26
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NLS Pharmaceutics  (NAS:NLSP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NLS Pharmaceutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Traded in Other Exchanges
N/A
Address
The Circle 6, Zurich, CHE, 8058
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

NLS Pharmaceutics (NLS Pharmaceutics) Headlines